Analysts at Stifel Nicolaus Reiterated their “Buy” rating for Watsco (WSO) with $191.0 PT; Sangamo Therapeutics (SGMO) Shorts Increased By 6.56%

Sangamo Therapeutics Incorporated (NASDAQ:SGMO) had an increase of 6.56% in short interest. SGMO’s SI was 8.39 million shares in January as released by FINRA. Its up 6.56% from 7.87 million shares previously. With 1.29M avg volume, 7 days are for Sangamo Therapeutics Incorporated (NASDAQ:SGMO)’s short sellers to cover SGMO’s short positions. The SI to Sangamo Therapeutics Incorporated’s float is 12.69%. The stock increased 1.43% or $0.25 during the last trading session, reaching $17.75. About 702,115 shares traded. Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has risen 29.78% since January 21, 2017 and is uptrending. It has outperformed by 13.08% the S&P500.

Among 10 analysts covering Watsco (NYSE:WSO), 7 have Buy rating, 2 Sell and 1 Hold. Therefore 70% are positive. Watsco has $207.0 highest and $103 lowest target. $153.88’s average target is -12.50% below currents $175.87 stock price. Watsco had 32 analyst reports since September 11, 2015 according to SRatingsIntel. Stifel Nicolaus maintained Watsco, Inc. (NYSE:WSO) on Tuesday, July 25 with “Buy” rating. As per Wednesday, June 1, the company rating was initiated by Susquehanna. As per Friday, June 23, the company rating was maintained by Stifel Nicolaus. The stock of Watsco, Inc. (NYSE:WSO) has “Underweight” rating given on Monday, April 18 by Barclays Capital. As per Wednesday, July 26, the company rating was maintained by Morgan Stanley. Robert W. Baird maintained Watsco, Inc. (NYSE:WSO) on Thursday, August 31 with “Buy” rating. The stock of Watsco, Inc. (NYSE:WSO) has “Buy” rating given on Friday, January 12 by Susquehanna. The rating was initiated by SunTrust on Monday, June 6 with “Buy”. Robert W. Baird maintained the stock with “Outperform” rating in Thursday, April 21 report. The stock of Watsco, Inc. (NYSE:WSO) earned “Underweight” rating by Barclays Capital on Monday, October 5.

Watsco, Inc., together with its subsidiaries, distributes air conditioning, heating, and refrigeration equipment; and related parts and supplies in the United States, Canada, Mexico, and Puerto Rico. The company has market cap of $5.78 billion. The firm distributes equipment, including residential central air conditioners; gas, electric, and oil furnaces; commercial air conditioning and heating equipment and systems; and other specialized equipment. It has a 32.26 P/E ratio. It also distributes various parts comprising replacement compressors, evaporator coils, motors, and other component parts; and supplies, such as thermostats, insulation material, refrigerants, ductwork, grills, registers, sheet metal, tools, copper tubing, concrete pads, tapes, adhesives, and other ancillary supplies.

Investors sentiment increased to 1.58 in Q3 2017. Its up 0.13, from 1.45 in 2017Q2. It increased, as 29 investors sold Watsco, Inc. shares while 68 reduced holdings. 49 funds opened positions while 104 raised stakes. 28.54 million shares or 1.86% more from 28.02 million shares in 2017Q2 were reported. Ww Asset reported 2,341 shares stake. Commonwealth Equity Inc owns 1,439 shares for 0% of their portfolio. Cap Advsrs Ltd Limited invested in 0.02% or 325 shares. Bb&T Corp accumulated 19,289 shares. Thomson Horstmann & Bryant invested 0.1% of its portfolio in Watsco, Inc. (NYSE:WSO). Weaver C Barksdale Associate holds 0.03% of its portfolio in Watsco, Inc. (NYSE:WSO) for 149 shares. Northwestern Mutual Wealth Mngmt reported 308 shares. Federated Invsts Pa reported 0.01% of its portfolio in Watsco, Inc. (NYSE:WSO). Echo Street Cap Management Limited Liability Company, a New York-based fund reported 306,592 shares. Barclays Public Limited Liability Co reported 1,602 shares or 0% of all its holdings. Brookstone Capital reported 0.03% stake. Dimensional Fund Advsrs Limited Partnership has 0.02% invested in Watsco, Inc. (NYSE:WSO). Moreover, Riverhead Mgmt Ltd Co has 0.01% invested in Watsco, Inc. (NYSE:WSO) for 1,985 shares. Quantitative Systematic Strategies Limited Liability Company invested 0.29% of its portfolio in Watsco, Inc. (NYSE:WSO). Baillie Gifford & reported 0.14% stake.

The stock increased 1.26% or $2.19 during the last trading session, reaching $175.87. About 98,766 shares traded. Watsco, Inc. (NYSE:WSO) has risen 8.75% since January 21, 2017 and is uptrending. It has underperformed by 7.95% the S&P500.

Analysts await Watsco, Inc. (NYSE:WSO) to report earnings on February, 13. They expect $1.00 EPS, up 23.46% or $0.19 from last year’s $0.81 per share. WSO’s profit will be $32.85M for 43.97 P/E if the $1.00 EPS becomes a reality. After $1.82 actual EPS reported by Watsco, Inc. for the previous quarter, Wall Street now forecasts -45.05% negative EPS growth.

Since August 11, 2017, it had 0 insider purchases, and 6 sales for $1.36 million activity. $445,597 worth of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) was sold by RINGO WILLIAM R. $119,740 worth of stock was sold by Herberts Curt A. III on Friday, August 11. 5,000 shares were sold by Conner Edward R., worth $85,545 on Monday, January 8.

Sangamo Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company has market cap of $1.50 billion. The companyÂ’s proprietary zinc finger DNA-binding protein technology enables specific genome editing and gene regulation. It currently has negative earnings. The ZFPs could be engineered to make ZFP nucleases (ZFNs), proteins that could be used to specifically modify DNA sequences by adding or knocking out specific genes; and ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off.

Among 10 analysts covering Sangamo Biosciences (NASDAQ:SGMO), 7 have Buy rating, 1 Sell and 2 Hold. Therefore 70% are positive. Sangamo Biosciences had 22 analyst reports since August 8, 2015 according to SRatingsIntel. Wedbush maintained Sangamo Therapeutics, Inc. (NASDAQ:SGMO) rating on Wednesday, November 15. Wedbush has “Hold” rating and $6.0 target. The company was maintained on Saturday, August 8 by JP Morgan. The stock of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has “Hold” rating given on Monday, August 14 by Wedbush. The rating was downgraded by PiperJaffray on Wednesday, October 19 to “Neutral”. The company was maintained on Thursday, August 10 by Piper Jaffray. The firm has “Buy” rating by Cowen & Co given on Friday, September 4. The rating was reinitiated by Jefferies with “Buy” on Friday, October 23. The rating was initiated by Wells Fargo on Friday, December 4 with “Outperform”. JP Morgan maintained the stock with “Buy” rating in Thursday, September 3 report. The stock has “Buy” rating by Jefferies on Wednesday, September 2.